Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Linetzky

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Heart (British Cardiac Society)|July 31, 2024
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trialHarlan M Krumholz, James A de Lemos, Naveed Sattar, et al.
Journal of the American College of Cardiology|June 3, 2026
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc AnalysisNaveed Sattar, Bruno Linetzky, Giacomo Ruotolo, et al.
JAMA Internal Medicine|November 24, 2025
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 TrialDeborah B Horn, Bruno Linetzky, Melanie J Davies, et al.
European Journal of Heart Failure|September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Felix Mahfoud, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Obesity (Silver Spring, Md.)|June 23, 2025
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trialCarolyn S P Lam, Angel Rodriguez, Ali Aminian, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Heart (British Cardiac Society)|July 31, 2024
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trialHarlan M Krumholz, James A de Lemos, Naveed Sattar, et al.
Journal of the American College of Cardiology|June 3, 2026
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc AnalysisNaveed Sattar, Bruno Linetzky, Giacomo Ruotolo, et al.
JAMA Internal Medicine|November 24, 2025
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 TrialDeborah B Horn, Bruno Linetzky, Melanie J Davies, et al.
European Journal of Heart Failure|September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Felix Mahfoud, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Obesity (Silver Spring, Md.)|June 23, 2025
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trialCarolyn S P Lam, Angel Rodriguez, Ali Aminian, et al.
Pageof 3